Grapefruit Products

Avoid concomitant intake of grapefruit as it acts as a strong CYP3A4 inhibitor.

Grapefruit products should be avoided due to CYP3A4 inhibition, which increases abemaciclib exposure and toxicity risk.

May increase axitinib plasma concentrations and should be avoided.

Grapefruit may inhibit CYP3A and increase ceritinib exposure. Do not consume grapefruit or grapefruit juice during treatment.

Strong CYP3A4 inhibitor increases erlotinib exposure, raising risk of exposure-related toxicity. Avoid co-administration or reduce erlotinib dosage if unavoidable.

Strong CYP3A4 inhibitor that increases erlotinib exposure and risk of exposure-related toxicity. Avoid concomitant use.

Strong CYP3A4 inhibitor; coadministration may increase larotrectinib plasma concentrations and increase adverse reactions. Avoid coadministration.

CYP3A inhibitor that may increase nifedipine exposure. Careful monitoring and dose adjustment necessary; consider lowest dose.

Strong CYP3A inhibitor. Increases nirogacestat exposure, which may increase risk of adverse reactions.

Grapefruit is a CYP3A4 inhibitor that may increase sirolimus concentrations, increasing the risk of adverse reactions. Concomitant use should be avoided.

Food or drink containing grapefruit should be avoided during treatment with JOURNAVX. Grapefruit inhibits CYP3A, increasing suzetrigine exposure.

Grapefruit may increase exposure of cabozantinib, increasing risk of exposure-related adverse reactions. Avoid coadministration or reduce CABOMETYX dosage.

Grapefruit increases exposure to colchicine. Advise patients to avoid grapefruit when taking colchicine.

Grapefruit may increase plasma concentrations of crizotinib, increasing risk of adverse reactions. Avoid concomitant use.

Grapefruit products contain CYP3A inhibitors that increase entrectinib concentrations. Avoid grapefruit products during treatment.

CYP3A4 inhibitor that increases serum concentrations of estradiol and dienogest.

Contains strong or moderate CYP3A inhibitors. Should be avoided during ibrutinib treatment to prevent increased ibrutinib concentrations.

CYP3A4 inhibitor may decrease metabolism of ifosfamide to its active alkylating metabolites, potentially decreasing effectiveness of ifosfamide treatment.

Grapefruit contains components that moderately inhibit CYP3A and may increase ivacaftor exposure. Avoid food or drink containing grapefruit.

Avoid consumption of grapefruit or Seville oranges during lonafarnib therapy due to CYP3A inhibition.

Grapefruit contains strong or moderate CYP3A inhibitors that increase lurbinectedin systemic exposure, which may increase incidence and severity of adverse reactions.

Moderate or strong CYP3A inhibitor that may increase pexidartinib concentrations, increasing incidence and severity of adverse reactions. Reduce TURALIO dosage if concomitant use cannot be avoided.

Grapefruit is a moderate CYP3A inhibitor. Concomitant use increases rilzabrutinib exposure and risk of adverse reactions.

Strong CYP3A4 inhibitor that increases upadacitinib exposure. Food or drink containing grapefruit should be avoided during treatment.

Food or drink containing grapefruit should be avoided. Grapefruit moderately inhibits CYP3A, which may increase exposure of vanzacaftor, tezacaftor, and deutivacaftor.